These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 34086251)

  • 1. Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015-2020.
    Huntemann N; Rolfes L; Pawlitzki M; Ruck T; Pfeuffer S; Wiendl H; Meuth SG
    Drugs; 2021 Jun; 81(9):1031-1063. PubMed ID: 34086251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotection and neuroregeneration in multiple sclerosis.
    Stangel M
    J Neurol; 2008 Dec; 255 Suppl 6():77-81. PubMed ID: 19300964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remyelination in multiple sclerosis: from concept to clinical trials.
    Kremer D; Göttle P; Flores-Rivera J; Hartung HP; Küry P
    Curr Opin Neurol; 2019 Jun; 32(3):378-384. PubMed ID: 30865009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015-2020.
    Rolfes L; Pawlitzki M; Pfeuffer S; Huntemann N; Wiendl H; Ruck T; Meuth SG
    BioDrugs; 2020 Oct; 34(5):587-610. PubMed ID: 32785877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of neuroprotective and alternative treatment strategies.
    Meuth SG; Bittner S; Ulzheimer JC; Kleinschnitz C; Kieseier BC; Wiendl H
    BioDrugs; 2010 Oct; 24(5):317-30. PubMed ID: 20795753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis.
    Aktas O; Kieseier B; Hartung HP
    Trends Neurosci; 2010 Mar; 33(3):140-52. PubMed ID: 20045200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of immunomodulatory treatment strategies.
    Ulzheimer JC; Meuth SG; Bittner S; Kleinschnitz C; Kieseier BC; Wiendl H
    BioDrugs; 2010 Aug; 24(4):249-74. PubMed ID: 20623991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010-2015.
    Pfeuffer S; Ruck T; Kleinschnitz C; Wiendl H; Meuth SG
    Expert Rev Neurother; 2016 Jun; 16(6):689-700. PubMed ID: 27058174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic strategies in multiple sclerosis: a focus on neuroprotection and repair and relevance to schizophrenia.
    Inglese M; Petracca M
    Schizophr Res; 2015 Jan; 161(1):94-101. PubMed ID: 24893901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietin as neuroprotective and neuroregenerative treatment strategy: comprehensive overview of 12 years of preclinical and clinical research.
    Sargin D; Friedrichs H; El-Kordi A; Ehrenreich H
    Best Pract Res Clin Anaesthesiol; 2010 Dec; 24(4):573-94. PubMed ID: 21619868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optic neuritis as a phase 2 paradigm for neuroprotection therapies of multiple sclerosis: update on current trials and perspectives.
    Aktas O; Albrecht P; Hartung HP
    Curr Opin Neurol; 2016 Jun; 29(3):199-204. PubMed ID: 27035900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neuroprotection in the treatment of multiple sclerosis].
    Zipp F; Gold R
    Nervenarzt; 2011 Aug; 82(8):973-7. PubMed ID: 21761185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis.
    Villoslada P; Steinman L
    Expert Opin Investig Drugs; 2020 May; 29(5):443-459. PubMed ID: 32299268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of laquinimod and its therapeutic potential in multiple sclerosis.
    Thöne J; Gold R
    Expert Opin Pharmacother; 2013 Dec; 14(18):2545-52. PubMed ID: 24215556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stepchild or Prodigy? Neuroprotection in Multiple Sclerosis (MS) Research.
    Rottlaender A; Kuerten S
    Int J Mol Sci; 2015 Jul; 16(7):14850-65. PubMed ID: 26140377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remyelinating and neuroprotective treatments in multiple sclerosis.
    Stangel M
    Expert Opin Investig Drugs; 2004 Apr; 13(4):331-47. PubMed ID: 15102584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurodegeneration and neuroprotection in multiple sclerosis.
    Stangel M
    Curr Pharm Des; 2012; 18(29):4471-4. PubMed ID: 22612743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What Have Failed, Interrupted, and Withdrawn Antibody Therapies in Multiple Sclerosis Taught Us?
    Krämer J; Wiendl H
    Neurotherapeutics; 2022 Apr; 19(3):785-807. PubMed ID: 35794296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New therapeutic strategies for remyelination in multiple sclerosis].
    Kremer D; Hartung HP; Stangel M; Küry P
    Nervenarzt; 2015 Aug; 86(8):934-46. PubMed ID: 26122637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges and needs in experimental therapies for multiple sclerosis.
    Lutterotti A
    Curr Opin Neurol; 2018 Jun; 31(3):263-267. PubMed ID: 29608446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.